An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
Now Recruiting: Moores Cancer Center (MCC), Associate Director for Community Outreach and Engagement (AD COE)
MCC is now seeking candidates from UC San Diego, San Diego State University (SDSU), and/or La Jolla Institute for Immunology (LJI) for the position of MCC AD COE.
The principal role of the MCC AD COE is to foster bidirectional communication between MCC members and community stakeholders in our catchment area and beyond. This communication plays a central role in MCC research efforts. As such, the MCC AD COE works directly with the MCC Community Advisory Board, COE staff, community collaborators, and MCC members. The MCC AD COE provides leadership to execute a focused mission, vision, and strategy for COE that aligns with not only the MCC Strategic Plan, but also COE-related initiatives of UC San Diego Health, UC San Diego Health Sciences, LJI, SDSU, and the larger UC San Diego campus. The MCC AD COE is charged with promoting and advancing innovative ideas, programs, and initiatives for outreach, engagement, and bidirectional communication with the San Diego community.
Any interested faculty members are encouraged to submit (1) a letter of interest that includes a vision for the position and (2) a current CV to Xochitl Villanueva at xvillanueva@health.ucsd.edu by Tuesday, April 18, 2023.
|
|
|
|
Angela Ballantyne, Ph.D., MCC Senior Director of Research Development and Translational Initiatives, was recognized in March 2023 for her 35-year anniversary with UC San Diego Health Sciences! For the past 4-1/2 years, she has worked with the MCC Director and MCC Executive Director for Administration to develop and administrate the entire portfolio of research, training, and education programs at MCC. We thank Dr. Ballantyne for her expertise, dedication, and contributions at not only MCC, but also UC San Diego Health Sciences.
|
|
|
Join the MCC Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
| Pharmacology Seminar Series
A Newfound Mechanism of Metabolite Regulation over Cell Cycle and Proliferation
Tuesday, April 18, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Zoom Link
Edward T. Chouchani, Ph.D.
Associate Professor of Cell Biology
Harvard Medical School
Associate Professor of Cancer Biology
Dana-Farber Cancer Institute
Hosted by Åsa Gustafsson, Ph.D.
|
|
|
| Cancer Biology and Signaling Seminar Series
Generation of Brain Cancer Avatars through Genome Engineering of Human iPSC
Wednesday, April 19, 2023 from 12:00 p.m. to 1:00 p.m. PT
MCC Comer Commons (Lunch Provided)
Zoom Link
Frank Furnari, Ph.D.
Professor, Department of Medicine
Divison of Regenerative Medicine
UC San Diego, School of Medicine
|
|
|
| Solid Tumor Therapeutics Seminar
Unconventional Signaling of CD28 and CTLA4: When Their Ligands Get on T Cells
Friday, April 21, 2023 from 12:00 p.m. to 12:45 p.m. PT
MCC Comer Commons
Zoom Link
Enfu Hui, Ph.D.
Associate Professor
Department of Cell and Developmental Biology
UC San Diego, School of Biological Sciences
|
|
|
| DRM Seminar Series
Decoding Human Hematopoietic Stem Cell Genesis and Self-renewal
Monday, April 24, 2023 from 3:00 p.m. to 4:00 p.m.
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
Zoom link available upon request
Hanna Mikkola, M.D., Ph.D.
Professor, Molecular, Cell, and Developmental Biology
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
University of California, Los Angeles
Hosted by Catriona Jamieson, M.D., Ph.D.
|
|
|
| Pharmacology Seminar Series
Exploring the Regulatory Apparatus of Bruton’s Tyrosine Kinase: A Drug Target for B-cell Cancers
Tuesday, April 25, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Zoom Link
Amy H. Andreotti, Ph.D.
Roy J. Carver Chair
University Professor of Biochemistry, Biophysics, and Molecular Biology
Iowa State University
Hosted by Alexandra Newton, Ph.D.
|
|
|
| SFG Cross-Lab Meeting: Mesirov Lab
Inter- and Intra-tumoral Heterogeneity of Circular Extrachromosomal DNA in High-risk Medulloblastoma
Wednesday, April 26, 2023 at 12:00 p.m. PT
MCC Comer Commons
Zoom Link
Owen Chapman, B.A.
Ph.D. Candidate, Mesirov and Chavez Labs
Bioinformatics and Systems Biology (BISB) Ph.D. Program
Department of Biomedical Informatics
UC San Diego, School of Medicine
Sanford Burnham Prebys Medical Discovery Institute
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
Better Health through Better Understanding: Cancer Disparities in San Diego
You are invited to attend Better Health Through Better Understanding: Cancer Disparities in San Diego on April 26, 2023 at 12:00 p.m., as part of National Minority and Multicultural Health Month. This webinar is free and open to all those interested. The webinar will target the cancer burden in San Diego County and research addressing cancer disparities.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC Cancer Research, Training, and Education Coordination (CRTEC). These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Administrative Supplement Announcement from the NCI Division of Cancer Control and Population Sciences (DCCPS)
NCI has released three separate Notice of Special Interest (NOSI) administrative supplement opportunities that are open to current awardees of numerous active NCI-funded grants. Please see the eligibility for each supplement in the links below.
|
-
Digital Health and PPC across the Cancer Control Continuum. This NOSI will support studies that seek to better understand (1) the effects of digital health tools/interventions on patient-provider communication, and/or (2) how patient-provider communication influences the relationship between digital health tools/interventions and cancer prevention and control outcomes (e.g., care quality, health behavior, and health equity. Studies that address under-resourced settings and underserved populations are of particular interest. More information can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-041.html
-
Health Policy Research in Cancer Prevention and Control. This NOSI will support studies that (1) generate new or utilize secondary data that operationalize policies hypothesized to affect cancer control at the geographic, provider, patient, and/or temporal level, (2) examine the effects of existing policies and/or simulate the potential effects of new policies, with an emphasis on understanding health disparities by examining differential impacts on disadvantaged groups, and (3) identify effective community-engaged strategies for dissemination or implementation of evidence to inform policy making. More information can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-044.html
-
Polygenic Risk Scores for Cancer Risk Assessment. This NOSI will support studies that (1) identify the potential for clinical utility (CU) of cancer-site specific polygenic risk scores (PRS) for cancer risk assessment, (2) describe the state of the science in terms of cancer-site specific PRS development and evaluation, (3) assess the current evidence for efficacy and/or effectiveness of PRS CU and potential benefits and harms of their clinical use (e.g., consideration of available screening and prevention interventions based on risk), and (4) propose criteria and optimal study designs and methods for which PRS are candidates for evaluation of CU through clinical trials. More information can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-046.html
|
Although more than one application per institution can be submitted, only one supplement application can be submitted per parent award. Please inform Divya Subramonian Ph.D. at dsubramonian@health.ucsd.edu if you plan to apply for any of these supplements.
NCI Application Deadline: Friday, April 21, 2023 by 5:00 p.m.
|
| |
2023 Bayer-Prostrate Cancer Foundation (PCF) Health Equity Research Awards for Health Equity Implementation Research for Patients with Prostate Cancer
Award provides up to a total of $200K/year per team over 2 years. Approximately $500K is designated for this award mechanism.
PCF and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Health Equity Research Awards to fund novel health equity implementation research projects, with the goal of reducing racial and ethnic disparities in the diagnosis and treatment of advanced prostate cancer. Proposals will be funded, depending on their level of innovation. Both PCF and Bayer seek high-risk, currently unfunded projects from only academic institutions in the United States.
LOI Submission Deadline: Friday, May 5, 2023 at 3:00 p.m. ET
Application Submission Deadline: Monday, July 10, 2023 at 3:00 p.m. ET
|
|
|
2023 Bayer-PCF Darolutamide Challenge Awards for Clinical Investigations on Novel Uses of Darolutamide in Prostate Cancer
Award provides up to a total of $1M per team. Approximately $3M is designated for this award mechanism.
PCF and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Challenge Awards to fund novel investigator-initiated clinical investigations that address correlative research for darolutamide in prostate cancer. Proposals will be funded, depending on their level of innovation. PCF and Bayer seek high-risk, currently unfunded projects from only academic institutions in the United States.
Application Submission Deadline: Monday, June 5, 2023 at 3:00 p.m. ET
|
|
|
Robert A. Winn, Diversity in Clinical Trials Career Development Award (Winn CDA) for Early-Stage Investigator Physicians
The Winn CDA provides $120K/year for 2 years to protect 40% of the awardee's work time for program participation.
The Winn CDA is a 2-year program designed to support the career development of early-stage investigator (ESI) physicians (as defined by NIH) who are underrepresented in medicine (URM) or who have a demonstrated commitment to increasing diversity in clinical research. The program prepares URM ESI physicians to become independent clinical trial investigators engaged in advancing health equity through their research and mentoring. The goal of the Winn CDA is to transform the clinical research landscape by building and strengthening partnerships between clinical investigators and the communities in which their patients reside to ultimately engage a patient population that mirrors the epidemiology of the disease studied.
Deadline: Friday, May 12, 2023
|
|
|
Department of Defense (DOD), Ovarian Cancer Research Program (OCRP), Clinical Trial Award (CTA)
The DOD Congressionally Directed Medical Research Program (CDMRP) will allot approximately $6.4M to fund one to three CTA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTA should not exceed $2.0M.
The DOD CDMRP OCRP CTA supports the rapid implementation of clinical trials with the potential to heavily influence the treatment or management of ovarian cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, and Phase 0 trials) to demonstrate the feasibility or inform the design of more advanced trials to large-scale trials to determine efficacy in relevant patient populations.
Required Pre-Application Submission Deadline: Friday, May 26, 2023
|
|
|
DOD OCRP Clinical Translational Research Award (CTRA)
The DOD CDMRP will allot approximately $3.2M to fund one to two CTRA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTRA should not exceed $2.0M.
The DOD CDMRP OCRP CTRA supports correlative studies that are associated with a clinical trial (past, ongoing, or future) to correlate various factors (genetic, biochemical, environmental, and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis, or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. Although not all-inclusive, research proposed under this mechanism may entail initiation of a deeper molecular analysis of clinical samples, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing or may be designed to generate clinically annotated and molecularly characterized experimental platforms (e.g., tissue arrays and patient-derived models). The award may not be used to directly support a clinical trial.
Required Pre-Application Submission Deadline: Friday, May 26, 2023
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Notice of Special Interest (NOSI): Administrative Supplements for NCI Division of Cancer Biology (DCB) Research Programs
You may submit applications for this initiative using any of the 24 funding opportunity announcements (FOAs) listed on the website above or any reissues of these announcement through the expiration date of this notice.
Through this NOSI, current awardees of DCB-led programs can apply for supplemental funding to support collaborative research projects. DCB-led or DCB-co-led programs appropriate for this NOSI include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.
Deadline: April 20, 2023
|
|
|
National Partnerships to Promote Cancer Surveillance Standards and Support Data Quality and Operations of National Program of Cancer Registries (NPCR)
This Notice of Funding Opportunity (NOFO) will enable organizations with a long-standing history of contributing to population-based cancer surveillance to apply their strengths and experience to work in tandem on cancer surveillance data standards and processes relevant to NPCR data collection.
The NOFO will support three proposed project components, each of which will target a specific set of strategies.
|
-
Cancer Data Standards Integration (Component 1). The recipient of this award will (1) manage the overall coordination of data item development, vetting, and definitions to be included in North American data standards, (2) evaluate the alignment of NAACCR standards with current and emerging national healthcare data standards, and (3) educate NPCR registries on data collection and evaluation to support high-quality data and central cancer registry practice.
- Cancer Staging and Care Quality (Component 2). The recipient of this award will (1) bridge clinical expertise on TNM cancer staging and cancer quality care measurements with the cancer surveillance system operations, which include assessment and incorporation of shared data items into NPCR software, and (2) provide education to NPCR and registry staff.
-
Electronic Cancer Pathology and Laboratory Reporting (Component 3). The recipient of this award will (1) develop and maintain interoperable cancer pathology and biomarker reporting laboratories standards and (2) engage in demonstration projects to facilitate report into NPCR registries.
|
LOI Deadline: April 28, 2023
Application Deadline: June 1, 2023
|
|
|
Provision of Training and Technical Assistance to Enhance Comprehensive Cancer Control Outcomes
This multi-component NOFO will fund up to three recipients who can demonstrate their national reach, cancer expertise, and capacity to provide training and technical assistance on multi-sectoral partnerships; policy, system, and environmental change approaches; health equity change; and social determinants of change approaches to National Comprehensive Cancer Control Program (NCCCP) recipients and cancer coalitions.
Deadline: May 8, 2023
|
|
|
NOSI: Administrative Supplement to Support Global Cancer Stigma Research
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding. Applications for this initiative must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
|
|
DOD Peer Reviewed Cancer Research Program (PRCRP) Impact Award
The DOD Congressionally Directed Medical Research Program (CDMRP) will allot $17.6M to fund approximately 11 PRCRP Impact Award applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP Impact Award should not exceed $1.0M.
Deadline: May 25, 2023
|
| Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional)
Application budgets may not exceed $250,000 in direct costs; maximum project length is 4 years.
Deadline: June 2, 2023
|
| Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)
Application budgets should reflect the actual needs of the proposed project but must not exceed $700,000 in direct costs per year; maximum project period is 5 years.
Deadline: June 30, 2023
|
|
|
Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
UG3: Application budgets may not exceed $250,000 in direct costs per year; maximum project period is 3 years.
UH3: Application budgets may not exceed $400,000 in direct costs per year; maximum project period is 2 years.
Deadline: June 30, 2023
|
| Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)
Application budgets should reflect the actual needs of the proposed project but must not exceed $700,000 in direct costs per year; maximum project period is 5 years.
Deadline: June 30, 2023
|
| DOD Ovarian Cancer, Investigator-Initiated Research Award
Amounts from $300K to $800K; pre-application required; due date April 17, 2023.
Deadline: July 21, 2023
|
|
|
DOD PRCRP Translational Team Science Award (TTSA)
The DOD CDMRP will allot $36M to fund approximately nine PRCRP TTSA applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP TTSA should not exceed $2.5M.
Deadline: July 25, 2023
|
| DOD PRCRP Patient Well-Being and Survivorship Award (PWSA)
The DOD CDMRP will allot $6.4M to fund approximately four PRCRP PWSA award applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP PWSA should not exceed $1.0M.
Deadline: July 25, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
|
|
| DOD Lung Cancer Translational Research Award
Amounts from $375K to $1.2M; pre-application required; due dates May 2 and May 10, 2023.
Deadline: August 3, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
|
|
NOSI: Career Development Opportunities for Research within the Mission of the NCI Division of Cancer Prevention (DCP)
This NOSI applies to due dates on or after February 12, 2023 and subsequent receipt dates through November 13, 2024.
|
| NOSI: Technology Development for Cancer Control and Population Science Research.
This NOSI applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024.
|
| NOSI: Research on the Etiology, Early Detection, Screening, and Prevention of Early-Onset Colorectal Cancer
This NOSI applies to due dates on or after January 5, 2023 and subsequent receipt dates through July 2, 2025.
|
|
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Postdoctoral Positions in Cancer Research
The laboratory of Dr. Thomas Kipps at MCC is seeking highly qualified and motivated postdoctoral fellows (scientists) to participate in state-of-the-art translational cancer research projects to investigate the genetics and immunology of cancer development and the generation of novel pharmacologic cancer therapeutics.
The Kipps laboratory investigates novel therapeutics for patients with leukemia and solid tumors. A particular focus of the laboratory is the function of onco-embryonic antigens, such as ROR1, which are selectively expressed by tumor cells and that contribute to malignant behavior. This involves the development and testing of novel agents that can target such antigens and/or their associated signaling pathways that contribute to the survival, growth, metastatic potential, and/or cancer stemness of neoplastic cells, even in the setting of conventional anti-cancer therapy. These studies can result in the development of more-effective therapies for patients with cancer.
Applicants for these postdoctoral positions must possess a Ph.D., strong analytical skills, proficiency in oral and written scientific presentations, and a demonstrated commitment to a career in cancer research.
These postdoctoral positions are offered preferably to candidates who have recently received their Ph.D. or have completed 3 years or less of post graduate education.
If interested, then submit a cover letter, curriculum vitae, statement of research interests, and the names and contact information of three references to Beth Lipski at elipski@ucsd.edu.
|
|
|
Curebound Connects: Equities in Cancer Research and Care
Tuesday, April 18, 2023 from 5:30 p.m. to 7:30 p.m.
Farmer & the Seahorse 10996 Torreyana Road, Suite 240 San Diego, CA 92121
Please join an interactive panel discussion and talk-back that will (1) explore the disparities that currently exist within areas of cancer research and care and (2) address how Curebound is building a strategy to drive more equitable outcomes through collaboration.
|
|
|
OncLive Institutional Perspectives in Cancer: Gynecologic Cancers
Monday, April 24, 2023 from 6:30 p.m. to 8:00 p.m.
Webinar Only
|
|
|
38th Annual Society for Thermal Medicine Meeting
April 23-27, 2023 Catamaran Resort Hotel, San Diego, CA
Visit the Society for Thermal Medicine website for programming, information, and registration.
|
|
|
NCI Virtual Workshop to Engage Multi-Cancer Detection (MCD) Assay Developers
Wednesday, May 3, 2023 from 1:00 p.m. to 5:00 p.m. ET
The NCI Division of Cancer Prevention is hosting a virtual workshop to explain a method of engagement for assay developers who are interested in having their assays considered for selection to the Vanguard study.
This interactive workshop is designed for multi-cancer detection (MCD) assay developers who are interested in participating in trials and studies to be run by a new Cancer Screening Research Network (CSRN) that is being established by NCI, which recognizes the importance of MCD assays and is interested in assessing their use as cancer screening tools. The CSRN is anticipated to start in January 2024, and its initial effort will be launching the Vanguard study (RFA-CA-23-020, RFA-CA-23-021, RFA-CA-23-022).
|
|
|
MCC Structural and Functional Genomics (SFG) Research Program Retreat
Friday, May 5, 2023
MCC Goldberg Auditorium and Lobby
Breakfast and lunch will be provided.
|
|
|
Joseph Califano, M.D.
Director, MCC
Director, Gleiberman Head and Neck Cancer Center
Professor, Department of Otolaryngology/Head and Neck Surgery UC San Diego, School of Medicine
Co-Leader, MCC, SFG Program
|
| Jill P. Mesirov, Ph.D.
Associate Vice Chancellor for Computational Health Sciences Professor, Department of Medicine
UC San Diego, School of Medicine Co-Leader, MCC, SFG Program
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
MPN Advocacy and Education International, San Diego Patient and Caregiver Program
Thursday, May 25, 2023 from 9:00 a.m. to 2:00 p.m.
Manchester Grand Hyatt San Diego
1 Market Place San Diego, CA 92101
This program will provide updated information about myeloproliferative neoplasms, available support, treatment options, symptom management, pertinent information regarding stem cell transplants, among other topics. Meet with not only MPN patients and caregivers, but also MPN specialists who will be speaking in the program.
Speakers will include the following:
|
- Dr. Catriona Jamieson, UC San Diego
- Dr. James Mangan, UC San Diego
-
Dr. Raajit Rampal, Memorial Sloan Kettering Cancer Center
|
|
|
Newly Opened Clinical Trials
|
|
|
64407564MMY4003: Pre-Approval Access Named Patient Program for Talquetamab (JNJ64407564) for Treating Physician Use in Relapsed or Refractory Multiple Myeloma
PI: Costello, C
NCT: NCT05757973
|
| | |
|
HC366-FCP2111: A Multicenter, Open-label, Phase 1a/b Study of HC7366 in Subjects With Advanced Solid Tumors
PI: Vu, P
NCT: NCT05121948
|
| | |
|
SHARED RESOURCE SPOTLIGHT
|
|
|
MCC Tissue Technology Shared Resource (TTSR) Receives Accreditation from the College of American Pathologists (CAP)
The CAP Accreditation Committee has awarded accreditation to the MCC TTSR, based on results of a recent on-site inspection as part of CAP's Accreditation Programs.
TTSR Director, Alfredo Molinolo, M.D., Ph.D., was advised of this national recognition and congratulated for the excellence of the services being provided. The MCC TTSR lab is one of more than 8,000 CAP-accredited facilities worldwide.
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program.
During the CAP accreditation process, which is designed to ensure the highest standards of care for all laboratory patients, inspectors examine a given laboratory's records and quality control of procedures for the preceding 2 years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, peruse the CAP Annual Report: https://www.cap.org/
|
|
|
-
de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S (STT), Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, et al. Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: Results from the expansion arm of a Phase Ib, open-label study. J Clin Oncol. 2023 MAR 22.
-
Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN (HEM), Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a Phase Ib study. J Clin Oncol. 2023 MAR 08.
-
Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander-Tetri BA, Cusi K, Loomba R (CCP), Given BD, Christianson DR, Garcia-Medel E, Yi M, Hamilton J, Yuen MF. A Phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol. 2023 APR 01.
- Kim YJ, Oh J, Jung S, Kim CJ, Choi J, Jeon YK, Kim HJ, Kim JW, Suh CH, Lee Y, Im SH, Crotty S (CBS), Choi YS. The transcription factor Mef2d regulates B:T synapse-dependent GC-TFH differentiation and IL-21-mediated humoral immunity. Sci Immunol. 2023 MAR 31.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below. To submit to the newsletter submission form, you must be logged into Google with your UC San Diego email account.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu. To continue receiving our emails, add us to your address book.
|
|
|
|